CARD9 and tuberculosis: Vaccine adjuvants bind to PRRs to trigger robust Th17 and Th1 responses through CARD9-medated signaling pathway, a promising protective mechanism against several infections including tuberculosis (TB), chlamydial infection or malaria in preclinical studies (72, 73).